NVCR NovoCure Limited

10.80
+0  (1%)
Previous Close 10.70
Open 10.80
Price To book 6.54
Market Cap 940.38M
Shares 87,072,000
Volume 400,916
Short Ratio 20.09
Av. Daily Volume 854,137

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PMA approval July 2016.
Optune system
Glioblastoma - cancer
Phase 3 commencement of enrollment announced February 15, 2017.
Tumor Treating Fields (TTFields) LUNAR
Non-small cell lung cancer (NSCLC)
Phase 2 data presented December 12, 2016. Further promising PFS data released March 31, 2017.
Tumor Treating Fields (TTFields) - INNOVATE
Ovarian cancer
Phase 2 data presented December 12, 2016.
Tumor Treating Fields (TTFields) - PANOVA
Pancreatic cancer
Phase 3 enrollment commenced October 2016. Enrollment to conclude in 2019.
Tumor Treating Fields (TTFields) METIS
Brain Metastases Originating from Non-Small Cell Lung Cancer
Phase 2 enrollment completion announced March 31, 2017. Data likely 2Q 2018.
Tumor Treating Fields (TTFields) STELLAR
Mesothelioma

Latest News

  1. Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston
  2. Novocure says drug shows better survival rates for cancer patients in late-stage trial
  3. CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence
  4. 5 Top Stocks to Buy in April
  5. What Investors Missed in the Market This Week
  6. Endo international, AngioDynamics Lead Biotech Movers
  7. ETFs with exposure to Novocure Ltd. : April 5, 2017
  8. Novocure and Cyclacel Pharmaceuticals Surge on Positive FDA Trial News
  9. After-hours buzz: PRTK, MRCY, NVCR
  10. Why NovoCure, Lumber Liquidators, and SodaStream International Jumped Today
  11. Here's Why NovoCure Ltd. Is Skyrocketing Today
  12. Why Bulls Are Piling Into Novocure Ltd (NVCR) Today
  13. Novocure Glioblastoma Drug Offers Survival Benefits
  14. Novocure Ltd. stock surges nearly 50% after positive late-stage trial results in brain cancer
  15. Novocure shares skyrocket 50% after positive trial results
  16. Biotech Movers: Novocure, United Therapeutics, Kite Pharma
  17. Why NovoCure Shares Are Skyrocketing
  18. Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients
  19. Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer
  20. Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer